JP2023531683A5 - - Google Patents
Info
- Publication number
- JP2023531683A5 JP2023531683A5 JP2022579019A JP2022579019A JP2023531683A5 JP 2023531683 A5 JP2023531683 A5 JP 2023531683A5 JP 2022579019 A JP2022579019 A JP 2022579019A JP 2022579019 A JP2022579019 A JP 2022579019A JP 2023531683 A5 JP2023531683 A5 JP 2023531683A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- treatment
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063041990P | 2020-06-21 | 2020-06-21 | |
| US202063041989P | 2020-06-21 | 2020-06-21 | |
| US202063041986P | 2020-06-21 | 2020-06-21 | |
| US202063041988P | 2020-06-21 | 2020-06-21 | |
| US202063041991P | 2020-06-21 | 2020-06-21 | |
| US63/041,988 | 2020-06-21 | ||
| US63/041,991 | 2020-06-21 | ||
| US63/041,986 | 2020-06-21 | ||
| US63/041,989 | 2020-06-21 | ||
| US63/041,990 | 2020-06-21 | ||
| US202163172560P | 2021-04-08 | 2021-04-08 | |
| US63/172,560 | 2021-04-08 | ||
| PCT/US2021/038264 WO2021262604A2 (en) | 2020-06-21 | 2021-06-21 | Administration of cebp-beta antagonist and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023531683A JP2023531683A (ja) | 2023-07-25 |
| JP2023531683A5 true JP2023531683A5 (https=) | 2025-01-20 |
Family
ID=79281738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579019A Pending JP2023531683A (ja) | 2020-06-21 | 2021-06-21 | ＣＥＢＰ－βアンタゴニストの投与及び使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230218717A1 (https=) |
| EP (1) | EP4168033B1 (https=) |
| JP (1) | JP2023531683A (https=) |
| KR (1) | KR20230027054A (https=) |
| CN (1) | CN115768458A (https=) |
| AU (1) | AU2021297172B2 (https=) |
| BR (1) | BR112022025880A2 (https=) |
| CA (1) | CA3180559A1 (https=) |
| FI (1) | FI4168033T3 (https=) |
| IL (1) | IL299104A (https=) |
| MX (1) | MX2022016478A (https=) |
| NZ (1) | NZ795026A (https=) |
| PT (1) | PT4168033T (https=) |
| WO (1) | WO2021262604A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025532391A (ja) * | 2022-10-07 | 2025-09-29 | サピエンス・セラピューティクス・インコーポレーテッド | Ｃ／ｅｂｐ－ベータアンタゴニスト及び免疫調節剤の使用 |
| WO2024216238A2 (en) * | 2023-04-13 | 2024-10-17 | Sapience Therapeutics, Inc. | Use of beta-catenin antagonist and immunomodulator |
| AU2024252321A1 (en) * | 2023-04-13 | 2025-10-16 | Sapience Therapeutics, Inc. | Administration of a beta-catenin antagonist and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516669A (ja) * | 2013-02-22 | 2016-06-09 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 転写因子ａｔｆ５の阻害により腫瘍細胞を阻害するための組成物および方法 |
| US10899834B2 (en) * | 2015-04-16 | 2021-01-26 | H. Lundbeck A/S | Anti-PACAP antibodies |
| WO2018152446A2 (en) * | 2017-02-20 | 2018-08-23 | Sapience Therapeutics, Inc. | Cell-penetrating atf5 polypeptides and uses thereof |
| WO2019136125A1 (en) * | 2018-01-03 | 2019-07-11 | Sapience Therapeutics, Inc. | Atf5 peptide variants and uses thereof |
| WO2020033555A2 (en) * | 2018-08-08 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells |
-
2021
- 2021-06-21 PT PT218289023T patent/PT4168033T/pt unknown
- 2021-06-21 KR KR1020227044587A patent/KR20230027054A/ko active Pending
- 2021-06-21 WO PCT/US2021/038264 patent/WO2021262604A2/en not_active Ceased
- 2021-06-21 JP JP2022579019A patent/JP2023531683A/ja active Pending
- 2021-06-21 NZ NZ795026A patent/NZ795026A/en unknown
- 2021-06-21 CA CA3180559A patent/CA3180559A1/en active Pending
- 2021-06-21 BR BR112022025880A patent/BR112022025880A2/pt unknown
- 2021-06-21 CN CN202180044276.8A patent/CN115768458A/zh active Pending
- 2021-06-21 MX MX2022016478A patent/MX2022016478A/es unknown
- 2021-06-21 US US18/011,171 patent/US20230218717A1/en active Pending
- 2021-06-21 EP EP21828902.3A patent/EP4168033B1/en active Active
- 2021-06-21 FI FIEP21828902.3T patent/FI4168033T3/fi active
- 2021-06-21 IL IL299104A patent/IL299104A/en unknown
- 2021-06-21 AU AU2021297172A patent/AU2021297172B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| De Groot et al. | CDK4/6 inhibition in early and metastatic breast cancer: A review | |
| Krishnan et al. | Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177 | |
| Franke et al. | Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review | |
| JP2023531683A5 (https=) | ||
| JP6351597B2 (ja) | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 | |
| Rochet et al. | Melanoma brain metastases and vemurafenib: need for further investigation | |
| CN105916501A (zh) | 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂 | |
| Aquilanti et al. | Immune checkpoint inhibitors for brain metastases: a primer for neurosurgeons | |
| EP4168008B1 (en) | A combination of belzutifan and lenvatinib for use in treating cancer | |
| AU2021297172B2 (en) | Administration of CEBPβ antagonist and methods of use | |
| Gligorov et al. | Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer | |
| US20210046106A1 (en) | Methods of treating cancer with androgen deprivation therapy in combination with an inhibitor of the sp1 transcription factor | |
| RU2858600C2 (ru) | Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли | |
| WO2020210829A1 (en) | Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies | |
| Shen et al. | Changjun Wang1, Yan Lin1, Yidong Zhou1, Feng Mao1, Hanjiang Zhu2, Jinghong Guan1, Xiaohui Zhang1 | |
| EP4598556A2 (en) | Use of c/ebp-beta antagonist and immunomodulator | |
| von Spreckelsen et al. | DDIS-36. BTP-7, A NOVEL PEPTIDE FOR THERAPEUTIC TARGETING OF MALIGNANT BRAIN TUMORS | |
| WO2025068348A1 (en) | Pharmaceutical combination of cxcr4 and pd-1 inhibitors for treating cancer | |
| ALIMKHODJAYEVA et al. | PRESCRIBING HORMONE THERAPY FOR BREAST CANCER: A PERSONALIZED APPROACH BASED ON BIOLOGICAL SUBTYPES | |
| HK40087480A (zh) | 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法 | |
| EP4694911A2 (en) | Administration of a beta-catenin antagonist and methods of use | |
| Akimoto et al. | Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes | |
| Shabaya et al. | Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer | |
| Ray-Coquard et al. | Methods: Eligible patients had high-grade PROC with≤ 4 prior lines of chemotherapy. Weekly paclitaxel (80 mg/m²) and increasing doses of ganetespib (100, 150 mg/m²) were given iv on days 1, 8, 15 in a 28 days cycle until disease progression or unacceptable toxicity. Endpoints were safety and determination of phase II dose. Dose limiting toxicity (DLT) was defined as grade 4 toxicity (with exceptions) occurring in cycles 1&2. |